Skip to content

Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery

Double-Blind, Randomized, Placebo -Controlled Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00763685
Enrollment
40
Registered
2008-10-01
Start date
2010-06-30
Completion date
2011-11-30
Last updated
2012-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

preoperative pain prophylaxis, postoperative pain

Brief summary

Primary Hypothesis: 1\. The analgesic effect of etoricoxib 120 mg administered 1 hour preoperatively is greater than that of placebo in the treatment of postoperative pain.

Interventions

DRUGetoricoxib

etoricoxib 120 mg, paracetamol 1 g

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
East Tallinn Central Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Type of gynaecologic surgery: * diagnostic laparoscopy * sterilization * removal of ovarial cyst * chromopertubation * laparoscopic myomectomy * laparoscopic fenestration of ovaria * laparoscopic adhesiolysis 2. Age 18-50 years. 3. Evaluated risk of anaesthetic procedure according to ASA (American Society of Anaesthesiologist) classification: ASA I or II. 4. Patients agreed to participate in the study and signed the informed consent.

Exclusion criteria

1. ASA III or more 2. Emergency surgery 3. Major laparoscopic surgery i.e. hysterectomy 4. Duration of surgery more than 90 minutes 5. Chronic pain 6. History of hypersensitivity to the active substance or to any of the excipients of study drug (Paracetamol or Etoricoxib) 7. Active peptic ulceration or active gastro-intestinal (GI) bleeding. 8. Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors. 9. Pregnancy and lactation 10. Severe hepatic dysfunction (serum albumin \< 25 g/l or Child-Pugh score ≥ 10). 11. Estimated renal creatinine clearance \< 30 mL/min. 12. Children and adolescents under 16 years of age. 13. Inflammatory bowel disease. 14. Congestive heart failure (NYHA II-IV). 15. Patients with hypertension whose blood pressure has not been adequately controlled. 16. Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease, unstable angina. 17. Patient has undergone coronary artery bypass graft surgery, angioplasty, or had myocardial infarction, cerebrovascular accident or transient ischemic attack within the past 6 months. 18. History of drug abuse.

Design outcomes

Primary

MeasureTime frame
Pain scale24 hours

Secondary

MeasureTime frame
Vomiting24 hours

Countries

Estonia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026